经动脉化疗栓塞联合索拉非尼治疗原发性大肝癌的效果

Effect of transcatheter arterial chemoembolization combined with Sorafenib in the treatment of primary liver cancer

目的探讨经动脉化疗栓塞(TACE)联合索拉非尼治疗原发性大肝癌的效果。方法选取2014年1月~2017年10月在我院收治的60例原发性大肝癌患者作为研究对象,根据不同治疗方式将其分为研究组、对照组,每组30例。对照组患者单纯进行TACE治疗,研究组在TACE治疗基础上给予索拉非尼进行联合治疗,并将两组治疗效果、肝功能指标及治疗期间不良反应发生率进行比较。结果研究组患者的临床总有效率显著高于对照组的,差异有统计学意义(P<0.05);两组患者术前ALB、ALT、TBil等肝功能指标的比较,差异无统计学意义(P>0.05);治疗后研究组患者ALT、TBil的指标明显优于对照组,差异有统计学意义(P<0.05);研究组患者的不良反应发生率显著低于对照组,差异有统计学意义(P<0.05)。结论相较于单一治疗方案,在TACE治疗基础上联合索拉非尼对原发性大肝癌患者进行治疗效果更为显著,可有效改善患者肝功能指标,且无明显毒副反应,用药安全性较高,具备较高临床运用价值。

Objective To investigate the effect of transcatheter arterial chemoembolization(TACE)combined with Sorafenib in the treatment of primary liver cancer.Methods From January 2014 to October 2017,60 patients with primary large hepatocellular carcinoma were selected as the research objects,and divided into study group and control group according to different treatment methods,30 cases in each group.Patients in the control group were treated with TACE alone,while patients in the study group were treated with Sorafenib on the basis of TACE.The therapeutic effect,liver function index and incidence of adverse reactions were compared between the two groups.Results The total clinical effective rate in the study group was significantly higher than that in the control group(P<0.05).There was no significant difference between the two groups in ALB,ALT and TBil before operation(P>0.05).After treatment,ALT and TBil in the study group were significantly better than those in the control group(P<0.05).The incidence of adverse reactions in the study group was significantly lower than that in the control group(P<0.05).Conclusion Compared with single treatment,combination of application of Sorafenib on the basis of TACE treatment in patients with primary liver cancer achieves more significant treatment effect,can effectively improve patients′liver function index with higher drug safety and no obvious side effects,which has high clinical application value.